Page last updated: 2024-11-06

tretazicar

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID89105
CHEMBL ID23330
SCHEMBL ID366755
SCHEMBL ID15691893
MeSH IDM0262599

Synonyms (74)

Synonym
MLS001066333
EU-0100200
cb 1954, solid
CB1 ,
5-(aziridin-1-yl)-2,4-dinitrobenzamide
tretazicar [inn]
benzamide, 5-(1-aziridinyl)-2,4-dinitro-
brn 5825582
ccris 1631
nsc 115829
cb-1954 ,
lopac-c-2235
NCGC00015220-01
LOPAC0_000200
nsc115829
5-(1-aziridinyl)-2,4-dinitrobenzamide
cb 1954
21919-05-1
2,4-dinitroethyleneiminobenzamide
5-aziridinyl-2,4-dinitrobenzamide
2,4-dinitro-5-ethyleneiminobenzamide
5-aziridino-2,4-dinitrobenzamide
cb 954
wln: t3ntj ar cvz dnw fnw
nsc-115829
smr000326847
MLS000859988
DB04253
tretazicar
cb1954
NCI60_000357
NCGC00093675-02
NCGC00093675-01
NCGC00015220-02
C 2235
NCGC00015220-04
CHEMBL23330 ,
bdbm50004681
5-aziridin-1-yl-2,4-dinitro-benzamide
HMS3260H21
7865d5d01m ,
unii-7865d5d01m
CCG-204295
HMS2233F04
NCGC00015220-03
benzamide,5-(1-aziridinyl)-2,4-dinitro-
LP00200
S7829
HMS3369C05
tox21_500200
NCGC00260885-01
SCHEMBL366755
SCHEMBL15691893
5-[aziridin-1-yl]-2,4-dinitrobenzamide
AC-35276
mfcd00869490
DTXSID00176335
AKOS030239859
AS-63985
cb1954(tretazicar)
J-014359
sr-01000075746
SR-01000075746-1
5-aziridin-1-yl-2,4-dinitrobenzamide
cb1954; tretazicar
CS-0007140
HY-13543
Q27095075
cb-954;cb1954;nsc 115829; cb 1954
BCP09250
SDCCGSBI-0050188.P002
NCGC00015220-05
C74095
C3656

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" -450 mV by cyclic voltammetry) and were more toxic to hypoxic than aerobic UV4 cells."( Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
Cliffe, S; Denny, WA; Palmer, BD; Wilson, WR, 1992
)
0.28
" Further experiments showed that NADH was toxic at the levels used to generate the active species (500 microM)."( Cytotoxicity and activation of CB1954 in a human tumour cell line.
Baer, J; Bagshawe, KD; Sunters, A, 1991
)
0.28
" All of the above inhibitors were also shown to potentiate the toxic effects of menadione against the Walker cell."( Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) in Walker cells.
Boland, MP; Friedlos, F; Knox, RJ; Kotsaki-Kovatsi, VP; Marchbank, T; Roberts, JJ, 1989
)
0.28
" Importantly, there was a highly significant linear relationship between cytotoxic potency and alkylating reactivity in both the aziridine and the mustard series, with the notable exception of 4, the 4-hydroxylamine of 1, which was 300-fold more toxic than predicted by this relationship."( Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Denny, WA; Helsby, NA; Palmer, BD; Pruijn, FB; Wheeler, SJ; Wilson, WR; Yang, S, 2003
)
0.32
" This paper reports the adverse and serious adverse events of the study."( Gene therapy for the treatment of hip prosthesis loosening: adverse events in a phase 1 clinical study.
de Poorter, JJ; Hoeben, RC; Huizinga, TW; Nelissen, RG; Obermann, WR, 2008
)
0.35
" The metabolites that obtained from the reduction of nitro benzamide prodrugs (1-4) by Ssap-NtrB, showed differential cytotoxic effects, with none toxic for HUVEC cells, moderate toxic for Hep3B cells, but highly toxic for PC3 cells."( Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Ay, M; Celik, A; Gungor, T; Kockar, F; Onder, FC; Tok, TT; Tokay, E; Yetis, G, 2018
)
0.48
"Amongst all metabolites of prodrugs after Ssap-NtrB reduction, N-(2,4- dinitrophenyl)-4-nitrobenzamide (3) was efficient and toxic in PC3 cells as comparable as CB1954."( Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Ay, M; Celik, A; Gungor, T; Kockar, F; Onder, FC; Tok, TT; Tokay, E; Yetis, G, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" This report summarizes a Phase I and pharmacokinetic study of the prodrug, CB1954."( Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
Anderson, D; Baddeley, J; Chung-Faye, G; Clark, J; Downes, M; Ferry, D; Harris, PA; Hussain, S; Kerr, DJ; Murray, PI; Palmer, D; Searle, P; Seymour, L, 2001
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" Finally, examination of nitroreductase/CB1954 in combination with conventional chemotherapy reveals a synergistic interaction with 5-fluorouracil."( Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Kerr, DJ; Milner, AE; Palmer, DH; Young, LS, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" No changes in pharmacokinetics were seen with repeated dosing in mice or with administration of the protective agent phenyl AIC."( CB 1954 revisited. I. Disposition kinetics and metabolism.
Talbot, K; White, RA; Workman, P, 1986
)
0.27
" Virus dose-response studies (s."( Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha, AH; Harris, PA; Kerr, DJ; Leung, H; Mountain, A; Searle, PF; Thomson, TA; Wrighton, CJ; Young, LS, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.09120.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency3.54810.180013.557439.8107AID1468
arylsulfatase AHomo sapiens (human)Potency0.19011.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.05620.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency12.99530.00419.984825.9290AID504444
gemininHomo sapiens (human)Potency1.45810.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency7.94330.00419.962528.1838AID2675
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Putative nitroreductaseStaphylococcus saprophyticus subsp. saprophyticus ATCC 15305 = NCTC 7292Ki5.96005.96006.62007.2800AID1581901
Nitroreductase AEscherichia coli O157:H7IC50 (µMol)0.89000.89000.89000.8900AID208704
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
2,4,6-trinitrotoluene catabolic processOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
2,4,6-trinitrotoluene catabolic processOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
NAD(P)H dehydrogenase (quinone) activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
6,7-dihydropteridine reductase activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
FMN bindingOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
oxidoreductase activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
identical protein bindingOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
protein homodimerization activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptorOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytosolOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
membraneOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
cytosolOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (224)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1581890Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280582Antiproliferative activity against chinese hamster V79 NTRpuro cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID267589Antiproliferative activity against human SKOV3 cells after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID216884Effective concentration of 10% cell survival for targets in V79 MCL (multicellular layer) cocultures2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID715666Ratio of apparent Kcat to apparent Km for Escherichia coli AzoR-mediated prodrug conversion using NADH as cofactor by steady state kinetic analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID200276Inhibitory activity against SKOV3 (human ovarian carcinoma) cell line in human2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID715466Ratio of apparent Kcat to apparent Km for Escherichia coli AzoR-mediated prodrug conversion using NADPH as cofactor by steady state kinetic analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID88863Ratio of cytotoxicity in a non-NTR-expressing SKOV compared to that in NTR-expressing SKOV.2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID267579Half life in phosphate buffer at pH 7 at 37 degC assessed as reduction by Escherichia coli nitroreductase by NR assay2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID230736Ratio of the activity in absence to that of presence of Escherichia coli nitroreductase V79 (chinese hamster fibroblast) cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID280587Antiproliferative activity against human wild type WiDr NTR-ve cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID267590Antiproliferative activity against NTR expressing human SKOV3 cells after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID565946Antitrypanosomal activity against Trypanosoma cruzi clone Cl-Brener infected in african green monkey Vero cells assessed as growth inhibition after 3 days by luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID215468Growth inhibition of aerobic chinese hamster ovary fibroblast UV4 cells using an exposure time of 18 hours1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
AID280585Antiproliferative activity against mouse EMT6 NTRpuro cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID111444In vivo activity against WiDr-nitroreductase tumors in mice at a dose of 200 (umol/kg); 12/532004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID715476Prodrug conversion in Tris-HCl buffer using NADPH as cofactor assessed as Escherichia coli NfsB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID715462Ratio of apparent Km for Escherichia coli NfsB-mediated prodrug conversion to apparent Km for Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated prodrug conversion2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID28845Solubility in alpha-MEM culture medium2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID1581906Cytotoxicity against human HUVEC cells assessed as cell viability at 9 to 150 uM after 24 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID267582Ratio for antiproliferative activity against NTR- V79 cells to NTR+ V79 cells after 72 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID233630Ratio of cytotoxicity against SKOV-3 cells in the absence of co-factor to the cytotoxicity in the presence of co-factor and NTR1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID200283Inhibitory activity against SKOV3 (human ovarian carcinoma) cell line with Escherichia coli nitroreductase combination after 18 hours drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID67766Inhibitory activity against EMT6 (mouse mammary carcinoma) murine cell line2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID233628Ratio of cytotoxicities against T78-1 cell line to NTR transfectant1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID715475Prodrug conversion in Tris-HCl buffer using NADH as cofactor assessed as Escherichia coli NfsB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID18270Km was determined2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID715661Prodrug conversion in Tris-HCl buffer assessed as Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID114259In vivo median growth delay against CD-1 nude mice bearing WiDr-nitroreductase tumors at a dose 200 (umol/kg)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID267592Activity against Escherichia coli nitroreductase2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID1581884Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1595316Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID634239Activation of Escherichia coli nitroreductase assessed as specific activity per mg of protein at 100 uM by measuring decrease in substrate concentration by HPLC analysis2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
The synthesis of 2-nitroaryl-1,2,3,4-tetrahydroisoquinolines, nitro-substituted 5,6-dihydrobenzimidazo[2,1-a]isoquinoline N-oxides and related heterocycles as potential bioreducible substrates for the enzymes NAD(P)H: quinone oxidoreductase 1 and E. coli
AID1333760Cytotoxicity against Chinese hamster T116 cells expressing Escherichia coli Nitroreductase assessed as reduction in cell viability after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID1581905Cytotoxicity against human PC3 cells assessed as cell viability at 9 to 150 uM after 48 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID231468Ratio between EMT6 and EMT6-NTRpuro was determined2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID215299Tested for the product of drug concentration and exposure time required to reduce UV4 cell survival under hypoxic condition by clonogenic assay1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID90458Ratio of cytotoxicity in a non-NTR-expressing WiDr compared to that in NTR-expressing WiDr.2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID202990In vitro for cytotoxicity against SKOV-3 cells in the presence of 1 mM NADH co-factor1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID280581Antiproliferative activity against chinese hamster wild-type V79 NTR-ve cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID267586Antiproliferative activity against human SKOV3 cells infected with 100 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID267588Ratio for antiproliferative activity against NTR- SKOV3 cells to NTR+ SKOV3 cells infected with 100 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID216893Inhibitory activity against V79 (chinese hamster fibroblast) cell line without Escherichia coli nitroreductase combination after 1 hour drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID715472Prodrug conversion in sodium phosphate buffer using NADPH as cofactor assessed as Bacillus amyloliquefaciens CAMR 0454 ywrO-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID280589Selectivity ratio of IC50 for WiDr NTR-ve cells to IC50 for WiDr NTRneo cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID110662In vivo activity against WiDr-nitroreductase tumors in mice at a dose of 200 (umol/kg); 31/532004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID1581886Substrate activity at Staphylococcus saprophyticus nitroreductase NtrB assessed as ratio of Kcat/Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 incubated for 30 mins by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID51925Cytotoxicity in non-NTR-expressing Chinese hamster fibroblast (V79).2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID1581894Substrate activity at Bacillus amyloliquefaciens nitroreductase ywrO assessed as ratio of Kcat/Km using NADPH as cofactor in sodium phosphate buffer at pH 7.5 by HPLC analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280583Selectivity ratio of IC50 for V79 NTR-ve cells to IC50 for V79 NTRpuro cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID9839Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
AID1333759Cytotoxicity against Chinese hamster DT7 cells expressing human NQO1 assessed as reduction in cell viability after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID208702Cytotoxicity in T78-1 (NR-negative) cell lines1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
AID205120Growth inhibitory potency against NTR-Transfected (nitroreductase) human ovarian cell line known as SKOV3-NTR neo cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID715465Prodrug conversion in buffer using NADH as cofactor assessed as Escherichia coli AzoR-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID232179Ratio of growth inhibition of NTR-transfected mouse mammary cell line to that of parental cell line (IC50 (NTR-)/IC50 (NTR+)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID565942Therapeutic index, ratio of IC50 for chinese hamster V79 cells to IC50 for Trypanosoma cruzi2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID565943Cytotoxicity against chinese hamster V79 cells after 6 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID226470Hypersensitivity factor was defined as the ratio of IC50(AA8) to IC50(UV4)1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
AID231700Ratio between WiDr and WiDr-NTRneo was determined2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID21950Solubility (alpha-MEM culture medium, containing 5% fetal calf serum)1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID548284Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID88862Cytotoxicity in non-NTR-expressing human ovarian carcinoma cell line (SKOV).2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID280588Antiproliferative activity against human WiDr NTRneo cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1595314Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor at 0 to 800 mM in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID715473Ratio of apparent Kcat to apparent Km for Escherichia coli NfsB-mediated prodrug conversion using NADH as cofactor by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID1581891Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280590Antiproliferative activity against human wild type Skov3 NTR-ve cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1581900Cytotoxicity against human PC3 cells expressing Staphylococcus saprophyticus nitroreductase NtrB assessed as reduction in cell viability in presence of NADH as cofactor after 48 hrs by SRB assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID267594Antiproliferative activity against NTR expressing human SKOV3 cells infected with 10 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID1581887Substrate activity at Bacillus amyloliquefaciens nitroreductase ywrO assessed as ratio of Kcat/Km using NADPH as cofactor in sodium phosphate buffer at pH 7.5 by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280600Clonogenic survival ratio of 3% V79 NTRpuro cells to 97% V79 NTRoua cells in co-culture2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID233629Ratio of cytotoxicities against WiDr cell line to NTR transfectant1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID280601Antitumor activity against mixed mouse EMT6/EMT6 NTRpuro cells injected in CD1 nude mouse assessed as cell kill at 200 umol/kg, ip in DMA/PEG after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID715664Prodrug conversion in Tris-HCl buffer assessed as Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated [5-(aziridin-1-yl)-4-hydroxyamino-2-nitrobenzamide] formation after 30 mins by HPLC analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID231692Ratio between SKOV3 and SKOV3-NTR neo was determined2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID715469Prodrug conversion in buffer using NADPH as cofactor assessed as Escherichia coli NfsA-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID548280Antimicrobial activity against Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID147403Catalytic constant determined to activate by FMN-dependent nitroreductase enzyme from Escherichia coli B (NTR)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme.
AID280623Antitumor activity against human 100% WiDr NTRneo tumor cells injected in CD1 nude mouse assessed as growth delay at 200 umol/kg, ip in DMA/PEG2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID232177Ratio of growth inhibition of NTR-transfected human colon cell line to that of parental cell line (IC50 (NTR-)/IC50 (NTR+)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID202989In vitro for cytotoxicity against SKOV-3 cells in the absence of co-factor1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID300739Activity of recombinant human NQO1 assessed as specific activity2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID715464Activity of Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB assessed as residual activity measured for 10 mins at 3 degC by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID267595Ratio for antiproliferative activity against NTR- SKOV3 cells to NTR+ SKOV3 cells infected with 10 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID715474Ratio of apparent Kcat to apparent Km for Escherichia coli NfsB-mediated prodrug conversion using NADPH as cofactor by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID565944Antitrypanosomal activity against Trypanosoma brucei BSF overexpressing NTR gene assessed as growth inhibition after 3 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID1581872Substrate activity at Staphylococcus saprophyticus nitroreductase NtrB assessed as Kcat using NADPH as cofactor in Tris-Cl buffer at pH 7.5 incubated for 30 mins by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID267584Antiproliferative activity against NTR expressing chinese hamster V79 cells after 1 hr2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID13317Ratio of Kcat to that of Km was determined2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID280599Clonogenic survival of V79 NTRoua cells after 5 hrs by MCL assay2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1333762Drug metabolism assessed as human NQO1-mediated compound reduction by measuring specific enzyme activity at 100 uM measured every 20 mins by HPLC based UV-Vis method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID548281Antimicrobial activity against Trypanosoma brucei NfxR12010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID216441Effective concentration of 10% cell survival for targets in WiDr MCL (multicellular layer) grown from targets2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID280586Selectivity ratio of IC50 for EMT6 NTR-ve cells to IC50 forEMT6 NTRpuro cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1595319Substrate activity at Staphylococcus saprophyticus nitroreductase assessed as ratio of Kcat/Km using NADPH as cofactor in presence of Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID715477Ratio of apparent Kcat to apparent Km for Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID715663Prodrug conversion in Tris-HCl buffer assessed as Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated [5-(aziridin-1-yl)-2-hydroxyamino-4-nitrobenzamide] formation after 30 mins by HPLC analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID228299The ratio of the cytotoxicities against UV4 cell line in the air and N2 was measured using clonogenic assay1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID1595315Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID267591Ratio for antiproliferative activity against NTR- SKOV3 cells to NTR+ SKOV3 cells after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID216439Effective concentration of 10% cell survival for activators in WiDr MCL (multicellular layer) cocultures2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID634235Activation of human NQO1 assessed as specific activity per mg of protein at 100 uM by measuring decrease in substrate concentration by HPLC analysis2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
The synthesis of 2-nitroaryl-1,2,3,4-tetrahydroisoquinolines, nitro-substituted 5,6-dihydrobenzimidazo[2,1-a]isoquinoline N-oxides and related heterocycles as potential bioreducible substrates for the enzymes NAD(P)H: quinone oxidoreductase 1 and E. coli
AID202991In vitro for cytotoxicity against SKOV-3 cells in the presence of 1 mM NADH co-factor and 1 ug/mL Escherichia coli B nitroreductase (NTR)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID548282Antimicrobial activity against Trypanosoma brucei NfxR22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID216618Growth inhibitory potency against NTR-Transfected (nitroreductase) human colon cell line known as WiDr-NTRneo cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID715467Prodrug conversion in buffer using NADPH as cofactor assessed as Escherichia coli AzoR-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID232178Ratio of growth inhibition of NTR-transfected human ovarian cell line to that of parental cell line (IC50 (NTR-)/IC50 (NTR+)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID227212Ratio of the cytotoxicities against drug induced aerobic Walker cells and chinese hamster ovary fibroblast line AA81994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID230739Ratio of the activity in absence to that of presence of the Escherichia coli nitroreductase in SKOV3 (human ovarian carcinoma) cell line infected at lower infection rate of 10 pfu/cell2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID280580Partition coefficient at pH 7.4 by shake-flask method2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID27581Partition coefficient (logP)2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID280592Selectivity ratio of IC50 for Skov3 NTR-ve cells to IC50 for Skov3 NTRneo cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID280591Antiproliferative activity against human Skov3 NTRneo cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID216895Inhibitory activity against V79 (chinese hamster fibroblast) cell line without Escherichia coli nitroreductase combination after 72 hours drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID267583Antiproliferative activity against chinese hamster V79 cells after 1 hr2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID228298CT10 ratio defined as ratio of CT10 (air) to that of CT10 (nitrogen))1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
AID267593Antiproliferative activity against human SKOV3 cells infected with 10 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID216892Inhibitory activity against V79 (chinese hamster fibroblast) cell line with Escherichia coli nitroreductase combination after 72 hours drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID267587Antiproliferative activity against NTR expressing human SKOV3 cells infected with 100 pfu/cell retrovirus after 18 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID233627Ratio of cytotoxicities against SKOV-3 cell line to NTR transfectant1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID17475Kcat was determined2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID1581907Cytotoxicity against human HUVEC cells assessed as cell viability at 9 to 150 uM after 48 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581877Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID26820Partition coefficient (logP)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID548283Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1581870Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID715667Activity of Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB assessed as residual activity measured for 10 mins at 15 degC by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID51926Ratio of cytotoxicity activity in a non-NTR-expressing V79 compared to that in NTR-expressing V79.2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID227233Tested for hypersensitivity factor which is the ratio of cytotoxicities against drug induced hypoxic UV4 cells and chinese hamster ovary fibroblast line AA81994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID216442Effective concentration of 10% cell survival for targets in WiDr MCL (multicellular layer) cocultures2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID267585Ratio for antiproliferative activity against NTR- V79 cells to NTR+ V79 cells after 1 hr2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID90457Cytotoxicity in non-NTR-expressing human colon carcinoma cell line (WiDr).2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID280594Clonogenic survival of 97% V79 NTRoua cells in co-cultures with 3% V79 NTRpuro cells after 5 hrs by MCL assay2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID200282Inhibitory activity against SKOV3 (human ovarian carcinoma) cell line infected at lower infection rate of 10 pfu/cell with Escherichia coli nitroreductase combination after 18 hours drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID216607In vitro cytotoxicity against man colon carcinoma line WiDr cell lines transfected with Escherichia coli B nitroreductase (NTR)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID1595310Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 48 hrs in presence of Staphylococcus saprophyticus nitroreductase and NADH by SRB assay2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID208701TE50 is termed as Bystander effect evaluated in T78-1 and T79-A3 cell lines1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
AID216593Inhibitory activity against WiDr (human colon carcinoma) cell line in human2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID1581876Substrate activity at Escherichia coli nitroreductase nfsA assessed as Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID140456Ratio of cytotoxicity in non-NTR-expressing EMT6 compared to that in NTR-expressing EMT6.2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID1581883Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID140455Cytotoxicity in non-NTR-expressing mouse mammary carcinoma cell line (EMT6).2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
AID21734Solubility in culture medium2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID267580Antiproliferative activity against chinese hamster V79 cells after 72 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID565941Therapeutic index, ratio of IC50 for chinese hamster V79 cells to IC50 for Trypanosoma brucei BSF2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID715468Ratio of apparent Kcat to apparent Km for Escherichia coli NfsA-mediated prodrug conversion using NADPH as cofactor by steady state kinetic analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID216749Inhibitory activity against V79 (Chinese hamster fibroblast) cell line in chinese hamster2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID232176Ratio of growth inhibition of NTR-transfected chinese hamster cell line to that of parental cell line (IC50 (NTR-)/IC50 (NTR+)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID1333761Cytotoxicity against Chinese hamster 186/6 cells expressing rat NQO1 assessed as reduction in cell viability after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID208703In vitro cytotoxicity against Chinese hamster V79-derived cell line T78-1 transfected with Escherichia coli B nitroreductase (NTR)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
AID1595318Substrate activity at Staphylococcus saprophyticus nitroreductase assessed as Km using NADPH as cofactor in presence of Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID300735Cytotoxicity against NQO2 expressing human RT112 cells by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID208704Cytotoxicity in T79-A3 (NR-positive) cell lines1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
AID300740Selectivity ratio of IC50 for RT112 cells in presence of cofactor NRH to IC50 for RT112 cells2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID300736Cytotoxicity against NQO2 expressing human RT112 cells in presence of NRH cofactor by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID67780Growth inhibitory potency against NTR-Transfected (nitroreductase) mouse mammary cell line known as EMT6-NTRpuro cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID57560Catalytic constant determined to activate by DT diaphorase in human cell lines2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme.
AID1581873Substrate activity at Bacillus amyloliquefaciens nitroreductase ywrO assessed as Kcat using NADPH as cofactor in sodium phosphate buffer at pH 7.5 by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1333758Cytotoxicity against Chinese hamster F179 transformed cells assessed as reduction in cell viability after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1581903Cytotoxicity against human Hep3B cells assessed as cell viability at 9 to 150 uM after 48 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1595317Substrate activity at Staphylococcus saprophyticus nitroreductase assessed as Kcat using NADPH as cofactor in presence of Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID200284Inhibitory activity against SKOV3 (human ovarian carcinoma) cell line without Escherichia coli nitroreductase combination after 18 hours drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID1595321Substrate activity at Staphylococcus saprophyticus nitroreductase assessed as ratio of Kcat/Km up to 80 mM using NADH as cofactor relative to CB1954/NfsB2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID1581878Substrate activity at Staphylococcus saprophyticus nitroreductase NtrB assessed as Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 incubated for 30 mins by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581904Cytotoxicity against human PC3 cells assessed as cell viability at 9 to 150 uM after 24 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280598Toxicity in ip dosed CD1 nude mouse in DMA/PEG2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID215462Hypoxic selectivity was measured as product of concentration and exposure time needed to reduce cell survival to 10% of control using UV4 cells at 10e6 /mL in the clonogenic assay1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
AID565945Cytotoxicity against african green monkey Vero cells after 6 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID231698Ratio between V79 and V79-NTRpuro was determined2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
AID216882Effective concentration of 10% cell survival for targets in V79 MCL (multicellular layer) grown from targets2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID1581869Substrate activity at Escherichia coli nitroreductase nfsA assessed as Kcat using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID230738Ratio of the activity in absence to that of presence of Escherichia coli nitroreductase in SKOV3 (human ovarian carcinoma) cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID267581Antiproliferative activity against NTR expressing chinese hamster V79 cells after 72 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
AID1581880Substrate activity at Bacillus amyloliquefaciens nitroreductase ywrO assessed as Km using NADPH as cofactor in sodium phosphate buffer at pH 7.5 by HPLC analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID216731Effective concentration of 10% cell survival for activators in V79 MCL (multicellular layer) cocultures2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID217048Growth inhibitory potency against NTR-Transfected (nitroreductase) chinese hamster fibroblast known as V79-NTRpuro cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
AID715471Ratio of apparent Kcat to apparent Km for Bacillus amyloliquefaciens CAMR 0454 ywrO-mediated prodrug conversion using NADPH as cofactor by steady state kinetic analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID1581902Cytotoxicity against human Hep3B cells assessed as cell viability at 9 to 150 uM after 24 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581901Binding affinity to Staphylococcus saprophyticus nitroreductase NtrB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581893Substrate activity at Staphylococcus saprophyticus nitroreductase NtrB assessed as ratio of Kcat/Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 incubated for 30 mins by HPLC analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1333763Drug metabolism assessed as Escherichia coli NR-mediated compound reduction by measuring specific enzyme activity at 100 uM measured every 20 mins by HPLC based UV-Vis method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
AID565947Activity of Trypanosoma brucei NTR expressed in Escherichia coli assessed as enzyme-mediated compound reduction by reverse phase HPLC2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID229968IC50 ratio for NR-positive and NR-negative cell lines1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
AID280584Antiproliferative activity against mouse wild type EMT6 NTR-ve cells after 18 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1595309Cytotoxicity in human PC3 cells assessed as reduction in cell viability at 180 nM measured after 48 hrs by SRB assay2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID1581909Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID280615Antitumor activity against mixed human 10% WiDr NTRneo/ 90% WiDr tumor cells injected in CD1 nude mouse assessed as growth delay at 200 umol/kg, ip in DMA/PEG2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID216896Inhibitory activity against V79 (chinese hamster fibroblast) cell line with Escherichia coli nitroreductase combination after 1 hour drug exposure2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
AID9486Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA81994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
AID280593Clonogenic survival of 3% V79 NTRpuro cells in co-cultures with 97% V79 NTRoua after 5 hrs by MCL assay2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (200)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (8.00)18.7374
1990's41 (20.50)18.2507
2000's90 (45.00)29.6817
2010's43 (21.50)24.3611
2020's10 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.10 (24.57)
Research Supply Index5.36 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (2.93%)5.53%
Reviews18 (8.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other181 (88.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC) [NCT00746590]Phase 21 participants (Actual)Interventional2008-09-30Terminated(stopped due to Study terminated prematurely by sponsor for business reason. One patient was enrolled.)
Phase I Trial of Replicative Defective Type 5 Adenovirus Vector Expressing Nitroreductase & GMCSF Given Via Trans-perineal Template-guided Intra-prostatic Injection Followed by iv CB1954 in Locally Relapsed Prostate Cancer Patients [NCT04374240]Phase 118 participants (Actual)Interventional2013-03-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00746590 (1) [back to overview]Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST

Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST

(NCT00746590)
Timeframe: every 6 weeks until progression

InterventionProportion of patients (Number)
Prolarix GroupNA

[back to top]